Severe Asthma: Clinical Phenotypes and Personalized Therapy

PROGRAM DESCRIPTION The FDA’s approval of several new tailored biologic therapies offers promise to a subset of patients with severe asthma, though identifying the asthma phenotypes (ie, eosinophilic and noneosinophilic) ...

PROGRAM DESCRIPTION
The FDA’s approval of several new tailored biologic therapies offers promise to a subset of patients with severe asthma, though identifying the asthma phenotypes (ie, eosinophilic and noneosinophilic) for which these new agents are most appropriate remains a key factor of their successful use. This CME e-learning Virtual Practice activity provides three modules that discuss the effective use of the newest biologic drugs and address key aspects of successfully assessing and treating patients with severe asthma.To complete the Virtual Practice, review all content in the Exam Rooms and the Main Conference Room; each room (module) confronts you with challenging clinical scenarios involving patients with severe asthma, similar to those you are likely to encounter in your own practice. Main Conference Room (Clinical Callout): Here you’ll find four patient vignettes that end at a critical clinical decision point. Your challenge: assess the symptoms, risk factors, and medical histories and choose the most appropriate next step from several possible clinical strategies. But be careful: only one option reflects current best practice!Exam Room 1: Margaret Thomas, 40, has had asthma for 10 years, but her symptoms have worsened recently and she has experienced two serious exacerbations. Was it a change in her medications? Is it related to her allergies?Exam Room 2: Al Carter, 55, was first diagnosed with asthma 15 years ago. In the last 3 months, his asthma has been uncontrolled despite the use of oral corticosteroids, and he was hospitalized. Are adjustments needed to Al’s regimen? If so, what are they?Resource Library: Offers downloadable content discussed in the Virtual Practice.

EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants should be able to:Discuss the two main types of severe asthma and the treatment implications of eachDiscuss the most recent Global Initiative for Asthma (GINA) guidelines for severe asthma treatment (Steps 4/5) Outline a personalized treatment plan, using targeted biologic therapies, to achieve and maintain control for patients with severe asthma based on underlying phenotypeDemonstrate how incorporating patient education and communication strategies can improve medication adherence and asthma control

---

Write the first review

Resource tags